| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC2564 |
| Trial ID | NCT04704921 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | RGX-314 |
| Phase | Phase2|Phase3 |
| Recruitment status | Recruiting |
| Title | A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE) |
| Year | 2021 |
| Country | United States |
| Company sponsor | AbbVie |
| Other ID(s) | RGX-314-2104 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||